The combination of GLP-1 and GIP activation is what separates tirzepatide from pure GLP-1 agonists like semaglutide, and clinical data suggests the dual mechanism produces superior weight loss outcomes
It's as if a fog has rolled into your brain, making simple tasks feel difficult
This shift is real, measurable in metabolic chamber studies, and largely independent of the GLP-1 medication's direct effects
Serving patients from Cardiff, Swansea, Newport, Monmouthshire, Bridgend and across South Wales
Clinical signs are indistinct and include lethargy, depression, ataxia, anorexia and intermittent vomiting, and in severe cases, can induce neurological disease and blindness in cats
Current batch COAs are available on our Certifications page